Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Virus Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Keratosis, Actinic 1Condylomata Acuminata 1

Interventions

3-ingenyl angelate 33Imiquimod 18Aminolevulinic Acid 16Gels 10Diclofenac 10Photochemotherapy 7methyl 5-aminolevulinate 6Fluorouracil 6Solutions 5LEO 43204 5BF-200 ALA 5tirbanibulin 4Ointments 4Cryotherapy 3SR-T100 2potassium dobesilate 1green tea extract polyphenone E 1beta-solamarine 1afamelanotide 1Therapies, Investigational 1Therapeutics 1Petrolatum 1Excipients 1Drugs, Generic 1Cryosurgery 1Control Groups 1AVX001 15-fluorouracil, salicylic acid drug combination 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Keratosis, Actinic × Therapies, Investigational × Clear all
NCT02404389 2021-01-05

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Novartis

Phase 2 Completed
82 enrolled 16 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡